# Ironwood Pharmaceuticals (IRWD) Stock Price, News & Catalysts
Canonical URL: https://biopharmsignal.com/company/IRWD
## Company Profile
- Ticker: IRWD
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
## Stock Data
- Close: 4.29 USD
- Market cap: 539931971.68 USD
- Last updated: 2026-09-03
## Business Overview
Ironwood Pharmaceuticals is a gastrointestinal-focused company anchored by Linzess and a pipeline aimed at digestive health. Its story is centered on GI commercialization and pipeline extension.
## Why The Stock Is Moving

The latest monitored company update is “Ironwood Pharmaceuticals to Participate in the Wells Fargo 21st Annual Healthcare Conference.” The corresponding closing-price reaction is not yet available.

## Geographic Base

Headquartered in the United States and listed on NASDAQ, Ironwood sits in specialty biopharma.

## Business Model

The business combines commercial GI revenue with pipeline optionality, so investors track prescription trends, partnership economics, and product durability.

## Landscape Position

Ironwood is a commercial specialty-pharma name whose valuation is tied to a limited number of digestive-health assets and their lifecycle.

## Future Catalysts

- Ironwood's catalysts are Linzess execution, GI commercial stability, and any pipeline or partnership update that clarifies the next growth vector. The company still needs the core franchise to stay durable.

## Recent News
- 2026-09-03 20:05 EST — [Ironwood Pharmaceuticals to Participate in the Wells Fargo 21st Annual Healthcare Conference](https://biopharmsignal.com/news/IRWD/ironwood-pharmaceuticals-to-participate-in-the-wells-fargo-21st-annual-healthcar-765d0f8e) — Source: Ironwood Pharmaceuticals
- 2026-08-06 11:05 EST — [Ironwood Pharmaceuticals Raises 2026 Full-Year Financial Guidance Building on Strong Second Quarter Results](https://biopharmsignal.com/news/IRWD/ironwood-pharmaceuticals-raises-2026-full-year-financial-guidance-building-on-st-2d099289) — Source: Ironwood Pharmaceuticals
- 2026-07-30 20:05 EST — [Ironwood Pharmaceuticals to Host Second Quarter 2026 Investor Update Call](https://biopharmsignal.com/news/IRWD/ironwood-pharmaceuticals-to-host-second-quarter-2026-investor-update-call-fd41929b) — Source: Ironwood Pharmaceuticals
- 2026-07-14 11:30 EST — [Ironwood Appoints Dr. Jeffrey Silber Chief Medical Officer and Head of Research and Drug Development; STARS-2 Trial Initiated in June and Is Now Actively Recruiting Patients](https://biopharmsignal.com/news/IRWD/ironwood-appoints-dr-jeffrey-silber-chief-medical-officer-and-head-of-research-a-b6d13a27) — Source: Ironwood Pharmaceuticals
- 2026-05-28 20:05 EST — [Ironwood Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference](https://biopharmsignal.com/news/IRWD/ironwood-pharmaceuticals-to-participate-in-the-jefferies-global-healthcare-confe-b815d20d) — Source: Ironwood Pharmaceuticals